The FORKO mouse as a genetic model for exploring estrogen replacement therapy
- PMID: 12063881
The FORKO mouse as a genetic model for exploring estrogen replacement therapy
Abstract
Objective: To evaluate how chronically estrogen deficient female FORKO mice with genetic disruption of the FSH receptor respond to estrogen therapy.
Study design: Subcutaneous estrogen agonist or antagonist therapy was initiated to study reproductive tissue response, adipose tissue mass and plasma lipid profiles.
Results: Within 36-48 hours of agonist administration, the classic measures of estrogenic activity were evident in the uterus and vagina. Older animals also responded to therapy during a 10-day period, indicating that estrogen receptor signaling systems are unaffected by aging. In these obese mutants, this short treatment decreased adipose tissue in all areas and corrected lipid abnormalities. Tamoxifen, a nonsteroidal mixed estrogen agonist and antagonist, had marginal effects on the uterus and body fat of FORKO mice, indicating differences in interaction.
Conclusion: In FORKO mice lacking ovarian estrogen, the receptors remain fully functional. Hence, this is a useful model for studying estrogen replacement therapy and helps resolve questions related to efficacy and actions.
Similar articles
-
Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice.Endocrinology. 2000 Nov;141(11):4295-308. doi: 10.1210/endo.141.11.7765. Endocrinology. 2000. PMID: 11089565
-
Dynamics of ovarian development in the FORKO immature mouse: structural and functional implications for ovarian reserve.Biol Reprod. 2003 Oct;69(4):1281-93. doi: 10.1095/biolreprod.103.015552. Epub 2003 Jun 11. Biol Reprod. 2003. PMID: 12801993
-
Perspectives on reproductive senescence and biological aging: studies in genetically altered follitropin receptor knockout [FORKO] mice.Exp Gerontol. 2004 Nov-Dec;39(11-12):1669-78. doi: 10.1016/j.exger.2004.05.009. Exp Gerontol. 2004. PMID: 15582283
-
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].Clin Calcium. 2004 Oct;14(10):85-93. Clin Calcium. 2004. PMID: 15577137 Review. Japanese.
-
[SERMs and uterus].Ann Med Interne (Paris). 2003 Mar;154(2):103-8. Ann Med Interne (Paris). 2003. PMID: 12746648 Review. French.
Cited by
-
Targeting gonadotropin receptor genes: reproductive biology, aging, and related health implications.Endocrine. 2005 Apr;26(3):219-26. doi: 10.1385/ENDO:26:3:219. Endocrine. 2005. PMID: 16034175 Review.
-
Current Animal Model Systems for Ovarian Aging Research.Aging Dis. 2022 Jul 11;13(4):1183-1195. doi: 10.14336/AD.2021.1209. eCollection 2022 Jul 11. Aging Dis. 2022. PMID: 35855343 Free PMC article. Review.